Cagrilintide + Semaglutide (10Mg)

Semaglutide —- GLP-1 Receptor Agonist

Semaglutide mimics the incretin hormone GLP-, acting primarily to:

• Suppress appetite via central nervous system signaling

• Slow gastric emptying

• Improve glucose-dependent insulin regulation

Its strength lies in reducing hunger and food reward, particularly cravings and large meal intake.

Cagrilintide — Long-Acting Amylin Analogue

Cagrilintide is a synthetic, long-acting analogue of amylin, a hormone co-secreted with insulin from pancreatic B-cells

Amylin’s physiological role includes:

• Promoting early satiety

• Slowing gastric emptying

• Regulating meal size and frequency

• Enhancing post-meal fullness

Cagrilintide is engineered to provide sustained amylin signaling without rapid degradation.

The power of semaglutide + Cagrilintide lies in non-overlapping but reinforcing mechanisms.

A. Central Appetite Control (Brain)

• Semaglutide acts mainly in the hypothalamus, reducing hunger drive and food-seeking behavior

•  Cagrilintide acts strongly in the area postrema and brainstem, amplifying satiety signal

Together, they:

• Suppress hunger initiation 

• Accelerate satiety onset

• Prolong post-meal fullness

This creates a multi-layered appetite blockade, rather than a single-point suppression.

B. Gastrointestinal Modulation

Both agents slow gastric emptying, but through different receptor systems:

• GLP-1 > vagal and enteric pathways

• Amylin > brainstem-mediated gastric control

The result is:

• Smallor mole capacity

• Reduced eating speed

• Lower glycemic excursions

Unlike simple caloric restriction , this combination alters eating behavior itself:

• Reduced portion size

• Less frequent hunger signals 

• Diminished hedonic (reward-driven)

• Increased sensitivity to fullness